Maplight Therapeutics (NASDAQ:MPLT) Director Troy Cox Acquires 15,620 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Troy Cox bought 15,620 shares of the stock in a transaction dated Tuesday, July 28th. The shares were acquired at an average price of $9.52 per share, with a total value of $148,702.40. Following the completion of the purchase, the director directly owned 15,620 shares of the company’s stock, valued at approximately $148,702.40. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Maplight Therapeutics Trading Up 24.3%

Maplight Therapeutics stock opened at $12.31 on Wednesday. The stock has a 50 day moving average of $31.54 and a 200-day moving average of $25.00. The stock has a market cap of $524.65 million and a P/E ratio of -0.30. Maplight Therapeutics, Inc. has a 52 week low of $9.10 and a 52 week high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, equities analysts predict that Maplight Therapeutics, Inc. will post -5.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Maplight Therapeutics during the fourth quarter valued at about $70,000. New York State Common Retirement Fund acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $93,000. MetLife Investment Management LLC acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $172,000. Finally, Walleye Capital LLC bought a new stake in Maplight Therapeutics during the fourth quarter worth approximately $205,000.

Maplight Therapeutics News Roundup

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: The ZEPHYR trial met its primary endpoint for the 210/3 mg twice-daily dose, which produced a statistically significant improvement in PANSS total score versus placebo. The dose also showed benefits on cognition, symptom severity and positive symptoms, with generally favorable tolerability. MapLight plans another potentially registrational trial and an FDA End-of-Phase 2 meeting. MapLight Announces Positive Topline Results
• Positive Sentiment: Analysts still see potential value after the selloff. HC Wainwright retained a “buy” rating with a $26 price target, while Morgan Stanley maintained “equal weight” with a $21 target—both above the recent trading level, although each firm reduced its target substantially. Analyst Rating Reports
• Neutral Sentiment: The twice-daily regimen’s success may preserve a development path for ML-007C-MA, but the results are not yet sufficient for approval. MapLight expects to conduct another trial to replicate the findings before pursuing registration.
• Negative Sentiment: The key disappointment was the once-daily dosing arm, which failed to show statistically significant symptom improvement. Investors viewed this as a major setback because a once-daily treatment could have offered a simpler, more convenient option. The news erased more than $1 billion in market value and sharply reduced confidence in the program. MapLight Once-Daily Trial Report
• Negative Sentiment: A law firm has announced an investor fraud investigation opportunity related to MapLight. The notice does not establish wrongdoing, but such announcements can add legal and reputational uncertainty to an already volatile stock. Investor Fraud Investigation Notice

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MPLT shares. Stifel Nicolaus boosted their price target on Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a report on Monday, June 1st. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Maplight Therapeutics in a research report on Monday, July 13th. BMO Capital Markets began coverage on shares of Maplight Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $46.00 price target for the company. Finally, Raymond James Financial began coverage on shares of Maplight Therapeutics in a research note on Wednesday, June 24th. They set a “strong-buy” rating and a $46.00 price objective on the stock. Four investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $34.42.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.